MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Evolving Treatment Modalities for Management of Patients Suffering From Disc Displacement With Reduction

Not Applicable
Completed
Conditions
Temporomandibular Joint Disc Displacement, With Reduction
Interventions
Device: Anterior repositioning appliance
Device: Low level laser therapy
First Posted Date
2022-01-18
Last Posted Date
2023-12-04
Lead Sponsor
Nourhan M.Aly
Target Recruit Count
27
Registration Number
NCT05194488
Locations
🇪🇬

Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Not Applicable
Completed
Conditions
Cosmetic Techniques
Interventions
First Posted Date
2021-12-22
Last Posted Date
2025-01-17
Lead Sponsor
University of Pennsylvania
Target Recruit Count
143
Registration Number
NCT05167864
Locations
🇺🇸

Penn Medicine, Philadelphia, Pennsylvania, United States

Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial

Phase 4
Conditions
Overactive Bladder
Overactive Bladder Syndrome
Interventions
First Posted Date
2021-12-15
Last Posted Date
2021-12-15
Lead Sponsor
Augusta University
Target Recruit Count
100
Registration Number
NCT05157295

A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

Phase 2
Completed
Conditions
Forehead Lines
Interventions
First Posted Date
2021-12-10
Last Posted Date
2023-08-14
Lead Sponsor
Allergan
Target Recruit Count
124
Registration Number
NCT05152576
Locations
🇺🇸

The Center for Dermatology Cosmetics & Laser Surgery /ID# 239776, Mount Kisco, New York, United States

🇺🇸

Dermatology Consulting Service /ID# 239779, High Point, North Carolina, United States

🇺🇸

Steve Yoelin MD Medical Assoc. Inc /ID# 239771, Newport Beach, California, United States

and more 5 locations

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Phase 3
Completed
Conditions
Glabellar Frown Lines
Interventions
Biological: Placebo
First Posted Date
2021-12-07
Last Posted Date
2024-10-21
Lead Sponsor
Galderma R&D
Target Recruit Count
132
Registration Number
NCT05146999
Locations
🇺🇸

Galderma Research Site, Spring, Texas, United States

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Phase 3
Completed
Conditions
Platysma Prominence
Interventions
First Posted Date
2021-11-26
Last Posted Date
2024-12-05
Lead Sponsor
AbbVie
Target Recruit Count
292
Registration Number
NCT05134649
Locations
🇺🇸

Steve Yoelin MD Medical Assoc. Inc /ID# 232004, Newport Beach, California, United States

🇺🇸

Susan H. Weinkle MD /ID# 232001, Bradenton, Florida, United States

🇺🇸

Research Institute of the Southeast, LLC /ID# 231974, West Palm Beach, Florida, United States

and more 26 locations

Evaluation of Botox Treatment on Chronical Scrotal Pain

Phase 4
Not yet recruiting
Conditions
Scrotum Disease
Chronic Pain
Interventions
Other: Sterile saline
First Posted Date
2021-11-08
Last Posted Date
2022-04-20
Lead Sponsor
Nicolai Skov Schiellerup
Target Recruit Count
50
Registration Number
NCT05112081
Locations
🇩🇰

Odense University Hospital, Odense C, Fyn, Denmark

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Phase 2
Completed
Conditions
Glabellar Lines
Interventions
First Posted Date
2021-10-29
Last Posted Date
2023-11-07
Lead Sponsor
Allergan
Target Recruit Count
328
Registration Number
NCT05100199
Locations
🇺🇸

Coleman Center For Cosmetic Dermatologic Surgery /ID# 230693, Metairie, Louisiana, United States

🇺🇸

Etre Cosmetic Dermatology and Laser Center /ID# 230437, New Orleans, Louisiana, United States

🇺🇸

The Eye Research Foundation /ID# 232544, Newport Beach, California, United States

and more 15 locations

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

Completed
Conditions
Glabellar Lines
Interventions
First Posted Date
2021-10-22
Last Posted Date
2025-02-12
Lead Sponsor
Galderma R&D
Target Recruit Count
250
Registration Number
NCT05089357
Locations
🇨🇳

Hangzhou Yanshuyuerong medical cosmetology clinic, Hangzhou, Zhejiang, China

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

Early Phase 1
Conditions
Glabellar Frown Lines
Interventions
First Posted Date
2021-10-19
Last Posted Date
2021-10-27
Lead Sponsor
Clinical Testing of Beverly Hills
Target Recruit Count
40
Registration Number
NCT05083286
Locations
🇺🇸

Steve Yoelin MD, Newport Beach, California, United States

🇺🇸

Clinical Testing of Beverly Hills, Encino, California, United States

© Copyright 2025. All Rights Reserved by MedPath